Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances

FDA-crafted legislative text emerges that generic industry says could weaken the incentive, but so far no changes are in the draft House and Senate bills.

FDA generic legislation — Generic advocates worry FDA's model legislation might render the 180-day exclusivity incentive almost irrelevant. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Advocates remain worried about the potential for an overhaul of the 180-day exclusivity incentive for generic drugs now that legislative text of the US Food and Drug Administration’s proposal has surfaced.

The House and Senate versions of the bill so far do not include any adjustments, but with the Senate committee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

13 Jun 2025

• By Sarah Karlin-Smith and Derrick Gingery

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

10 Jun 2025

• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.